Goal: To update understanding of the guidelines and reccomendations for management of iron-deficiancy anemia in patients on hemodialysis.
Examine how a facility's staff, including RNs, MDs, PAs, and dietitians, can take a collaborative approach to updating anemia management practices.
Identify strategies for implementing a maintenance IV Iron protocol to improve patient outcomes.
Discuss emerging infomration on ESA and IV Iron therapies and its impact on treating hemodialysis patients with anemia.
Richar Amerling, MD, disclosed that he is on the Consultant Presenter Bureau for Amgen, Inc., Ortho Biotech, and Watson Pharma, Inc. Andrea Easom, MA, MNSc, APN, BC, CNN-NP has disclosed that she is on the Consultant Presenter Bureau for Amgen, Inc. and Watson Pharma, Inc. Peter Juergensen, PA-C has disclosed that he receives grant/research support from Watson Pharma, Inc.
Note: This article is supported by a financial grant from Watson Pharm, Inc. This article has undergone peer review. The information in this article does not necessarily reflect the opinions of ANNA or the sponsor.